The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Identification of novel candidate protein biomarkers for the post-polio syndrome — Implications for diagnosis, neurodegeneration and neuroinflammation

Author

  • Henrik Gonzalez
  • Jan Ottervald
  • Kerstin C. Nilsson
  • Niclas Sjögren
  • Tasso Miliotis
  • Helena Von Bahr
  • Mohsen Khademi
  • Bodil Eriksson
  • Sven Kjellström
  • Ákos Végvári
  • Robert Harris
  • György Marko-Varga
  • Kristian Borg
  • Johan Nilsson
  • Thomas Laurell
  • Tomas Olsson
  • Bo Franzén

Summary, in English

Survivors of poliomyelitis often develop increased or new symptoms decades after the acute infection, a condition known as post-polio syndrome (PPS). The condition affects 20-60% of previous polio patients, making it one of the most common causes of neurological deficits worldwide. The underlying pathogenesis is not fully understood and accurate diagnosis is not feasible. Herein we investigated whether it was possible to identify proteomic profile aberrations in the cerebrospinal fluid (CSF) of PPS patients. CSF from 15 patients with well-defined PPS were analyzed for protein expression profiles. The results were compared to data obtained from nine healthy controls and 34 patients with other non-inflammatory diseases which served as negative controls. In addition, 17 samples from persons with secondary progressive multiple sclerosis (SPMS) were added as relevant age-matched references for the PPS samples. The CSF of persons with PPS displayed a disease-specific and highly predictive (p=0.0017) differential expression of five distinct proteins: gelsolin, hemopexin, peptidylglycine alpha-amidating monooxygenase, glutathione synthetase and kallikrein 6, respectively, in comparison with the control groups. An independent ELISA confirmed the increase of kallikrein 6. We suggest that these five proteins should be further evaluated as candidate biomarkers for the diagnosis and development of new therapies for PPS patients.

Publishing year

2009

Language

English

Pages

670-681

Publication/Series

Journal of Proteomics

Volume

71

Issue

6

Document type

Journal article

Publisher

Elsevier

Topic

  • Medical Engineering

Keywords

  • post-polio syndrome
  • CSF
  • proteomics
  • diagnosis
  • biomarkers
  • pathophysiology

Status

Published

ISBN/ISSN/Other

  • ISSN: 1874-3919